

Investors Newsletter

Number 11

Feb 25, 2017



To our Partners, Friends and Shareholders: 2017 is going to be very active.

We were just been granted the Israeli marketing approval (AMAR). The approval is for 3 years and is



אישור רישום בפנקס הציוד הרפואי

29380001 : ניתן בזאת אישור, כי בהתאם לבקשת רישום מס :
הציוד הרפואי (אבזורים / מכשירים רפואיים) (אמ"ר) הבא :

E-QURE BST	אי קיור בי.אס.טי	שם הציוד הרפואי
------------	------------------	-----------------

AMAR Certificate Title

going to be the base for our commercial activity in Israel. We are now ready to activate our distribution agreement that we have signed a year ago, with Chemipal Ltd. Simultaneously, we are filing to the ministry of health asking to be included in the Israeli National Health Basket such that our treatment may be reimbursed. We are waiting for their positive response. In the meanwhile, we intend to start commercial activity in the private market.

Last month we signed a new distribution agreement for the territory of Colombia in South America. The local distributor has committed to minimum annual purchases growing every year for 10 years, starting immediately after he has obtained the local marketing approval. This is expected somewhere in H2 2017.

Before starting our US study, we have asked the FDA to allow us to use few trial sites for the first 10 patients, rather than the single one they have approved us. Just a few days ago, we were informed by the FDA that he is accepting our request and allowing us to start the trial with up to five different institutions. This has major positive impact on the time frame planned for our study. Treating 10 patients in one single site would have taken us more than a year to complete, lengthening dramatically the total trial period. Now that we are allowed to recruit patients in 5 sites, it will shorten our time frame drastically.

We are preparing to register the clinical trial on clinicaltrials.gov, the official FDA site for clinical trials. We hope to start recruiting patients for the trials within a couple of months. For reminder, the study includes 90 patients, 45 of them with BST treatment and 45 with sham device. All patients will be those with stage 3 and 4 pressure ulcers.

We have completed to manufacture first 100 batch of commercial devices. Final quality testing is undergoing.



New devices ready for use, after testing

This batch is designated for launching commercial activity in Israel and Argentina, as well as conducting observational trials in Europe.

We have launched our investors relation program. We hired a professional company that is introducing us to the marketplace and helping us get investors visibility and recognition. We have also hired an PR company promoting our story in the media, internet and social media space. We spend 10 days in January road showing in the NY area, presenting our company to brokers, investors and

Investors Newsletter

Number 11

Feb 25, 2017



professionals.



After few days of IR road show

Two analysts article were published about us in the last two months. Please read and share them with others. Zacks Small Cap Research Update <https://t.co/6btaY500KV> and Ray Dirks article on Seeking Alpha

<http://seekingalpha.com/instablog/1240561-ray-dirks/4959985-public-health-crisis-chronic-wounds-cost-lives-50-billion-annually>

We are getting noticed. We have reached over 1000 followers on Twitter. Please look us up @EQUR_IR. Also, please follow us on LinkedIn https://www.linkedin.com/company/e-quire-corp-?trk=top_nav_home and be our friend on Facebook <https://www.facebook.com/E-Qure-Corp-802125043175676/>.

We are making efforts to get this year to a stage where we can up-list our company from OTCQB to NASDAQ. In the meanwhile, we are raising limited equity funding of \$0.5 at favorable market terms to bridge our financial needs until we up-list. If you need information, please Email us for details.

All our previous newsletters and announcements can be found also on our web site www.e-quire.com